Hokkaido University to Participate in BIO EUROPE 2025
2025.10.16
Hokkaido University will be participating BIO-Europe 2025, an international biopharma partnering conference to be held in Vienna, Austria, from November 3 to 5, 2025.
Official website: https://informaconnect.com/bioeurope/
Representatives from Hokkaido University in the fields of life sciences and biotechnology will share the University’s latest research achievements and technological innovations to explore the partnering opportunities including patent licensing and collaborative research with excellent companies worldwide.
Through participation in BIO-Europe 2025, Hokkaido University seeks to further promote international research exchange and contribute to the advancement of biopharmaceutical science and innovation.
Assets： Hokkaido University(BIO-EUROPE 2025)
Neurological Disorders
1.Therapeutic Protein for Promotion of Axon Regeneration in PNS and CNS
2.A new therapeutic peptides for Alzheimer's disease
3.Novel suppressors of TDP aggregation for the therapeutic implication of ALS and FTLD
4.A neutrophil NETs inhibitor for axon regeneration
2.A new therapeutic peptides for Alzheimer's disease
3.Novel suppressors of TDP aggregation for the therapeutic implication of ALS and FTLD
4.A neutrophil NETs inhibitor for axon regeneration
Drug Delivery System
5.A Novel Lipid for Hepatic stellate cells (HSC)
6.Optimized LNP for the spleen delivery
7.Novel Helper Lipids that accelerate endosomal escapes.
8.Lipid nanoparticles for ribonucleoprotein delivery for in vivo genome editing
9.Novel Delivery programs for NK cells for cancer treatment
6.Optimized LNP for the spleen delivery
7.Novel Helper Lipids that accelerate endosomal escapes.
8.Lipid nanoparticles for ribonucleoprotein delivery for in vivo genome editing
9.Novel Delivery programs for NK cells for cancer treatment
Oncology & Immunology
11.Pancreatic cancer treatment drugs
12.Intracellular delivery of anti-interleukin-6 and anti-interleukin-6 receptor antibodies and inhibition of cancer cell growth using PIECE
13.Treatment resistance reducing agent for treatment-resistant cancer
14.Hydrophilic-hydrophobic copolymers carrying Dichloroacetic acid on side chain and mecical use therof
15.Novel STING Agonist
16.STAP-1 Therapeutic Peptide for Autoimmune disease
12.Intracellular delivery of anti-interleukin-6 and anti-interleukin-6 receptor antibodies and inhibition of cancer cell growth using PIECE
13.Treatment resistance reducing agent for treatment-resistant cancer
14.Hydrophilic-hydrophobic copolymers carrying Dichloroacetic acid on side chain and mecical use therof
15.Novel STING Agonist
16.STAP-1 Therapeutic Peptide for Autoimmune disease
Metabolic & Chronic Diseases
17.Meflin is involved in the development of inflammatory diseases as a novel TNF receptor ligand.
18.Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition
19.Resolvin E3 Derivatives: Breakthrough Therapy for Insulin-Resistant Type 2 Diabetes
20.A repurposing drug candidate that can suppress rebound bone resorption after administration of anti-RANKL antibody, a treatment for osteoporosis
18.Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition
19.Resolvin E3 Derivatives: Breakthrough Therapy for Insulin-Resistant Type 2 Diabetes
20.A repurposing drug candidate that can suppress rebound bone resorption after administration of anti-RANKL antibody, a treatment for osteoporosis
Infectious & Diagnostic Technologies
21.Novel peptides for glaucoma treatment
22.Anti-photoaging topical agent that can be a repurposing drug candidate for skin aging diseases including xeroderma pigmentosum and skin cancer by removing senescent cells
23.Novel Antibodies for Marburg Virus Therapy
24.A Highly Cross-Neutralizing Antibody for Ebolavirus Therapy
25.Novel antibacterial peptides
26.Methods and kits for detecting human α-defensin HD5 and antibodies used in said methods and kits
28.Comprehensive detection method for parasites using portable NGS
22.Anti-photoaging topical agent that can be a repurposing drug candidate for skin aging diseases including xeroderma pigmentosum and skin cancer by removing senescent cells
23.Novel Antibodies for Marburg Virus Therapy
24.A Highly Cross-Neutralizing Antibody for Ebolavirus Therapy
25.Novel antibacterial peptides
26.Methods and kits for detecting human α-defensin HD5 and antibodies used in said methods and kits
28.Comprehensive detection method for parasites using portable NGS
Technology Platforms & Devices
10.Programmable “srRNA” therapeutics to induce skipping of target exons - Alternatives to splicing regulatory antisense oligonucleotides
27.Imaging Diagnosis of Hip Joint Disorders
29.Shortwave infrared fluorescent dyes for highly sensitive detection of tumors via EPR effect
30.Novel mammalian cell expression vectors capable of producing high levels of exogenous proteins
31.Widely applicable as a general strategy for the optimization of peptide sequences
32.Method for Temporal Evaluation of Reproductive Toxicity Using Bioluminescent Imaging and Genetically Modified Mice
27.Imaging Diagnosis of Hip Joint Disorders
29.Shortwave infrared fluorescent dyes for highly sensitive detection of tumors via EPR effect
30.Novel mammalian cell expression vectors capable of producing high levels of exogenous proteins
31.Widely applicable as a general strategy for the optimization of peptide sequences
32.Method for Temporal Evaluation of Reproductive Toxicity Using Bioluminescent Imaging and Genetically Modified Mice